We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
- Authors
Egaña, Larraitz; Auzmendi-Iriarte, Jaione; Andermatten, Joaquin; Villanua, Jorge; Ruiz, Irune; Elua-Pinin, Alejandro; Aldaz, Paula; Querejeta, Arrate; Sarasqueta, Cristina; Zubia, Felix; Matheu, Ander; Samprón, Nicolas
- Abstract
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Specifically, overall survival (OS) and progression-free survival (PFS) did not differ significantly by MGMT methylation status in our cohort. In contrast, both were longer in patients who received treatment, received more TMZ cycles, had a better general status and perform at least a partial resection. No association was detected between methylation of MGMT promoter and molecular markers such as ATRX, IDH, p53 and Ki67. These results indicate that MGMT methylation did not influence in patient survival in our cohort.
- Subjects
O6-Methylguanine-DNA Methyltransferase; DNA methyltransferases; DNA methylation; GLIOBLASTOMA multiforme; CANCER prognosis; PROMOTERS (Genetics); CANCER genetics; CANCER invasiveness
- Publication
Scientific Reports, 2020, Vol 10, Issue 1, pN.PAG
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-020-75477-9